Hungary Pharmaceuticals & Healthcare Q2 2019
We hold a subdued outlook for the Hungarian pharmaceutical market in the coming years, forecasting growth to beamong the slowest five in the Central and Eastern European (CEE) region. Medicine sales will be driven by the country’s growingpensionable population and high obesity rates, contributing to a greater burden of chronic diseases which require advancedtreatments. However, with an ageing population coupled with a declining workforce, the Hungarian government will face rising costpressures and a difficult revenue raising environment over the long term. Government encouragement of generic medicines andpricing pressures, combined with patent expirations, will depress overall prescription growth values.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook